Lead Product(s) : Loxicodegol
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
Details : The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee does not recommend NDA approval of Nektar's oxycodegol.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2020
Lead Product(s) : Loxicodegol
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
